Stratatech’s ExpressGraft begins human tests to treat diabetic foot ulcers

ExpressGraft-C9T1 is being used in first-round tests on a patient with diabetic foot ulcers — open sores that can affect patients with diabetes and can lead to amputation, said Mallinckrodt, the global pharmaceutical company whose Madison division, formerly Stratatech Corp., developed the tissue.


ExpressGraft-C9T1 is a genetically engineered, antimicrobial human skin substitute. It may benefit patients with “chronic, difficult-to-heal wounds such as those seen in patients with diabetes,” said Lynn Allen-Hoffmann, who was the founder and CEO of Stratatech and now is senior vice president of regenerative medicine at Mallinckrodt.